Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection

NCT04514484 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04514484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04514484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 22, 2021
Completion date
February 6, 2027
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced differentiated thyroid gland carcinoma, advanced head and neck carcinoma, advanced hepatocellular carcinoma, advanced kaposi sarcoma, advanced lung non-small cell carcinoma, advanced lung small cell carcinoma, advanced malignant solid neoplasm, advanced melanoma, advanced ovarian carcinoma, advanced prostate carcinoma, advanced renal cell carcinoma, advanced thyroid gland medullary carcinoma, advanced triple-negative breast carcinoma, advanced urothelial carcinoma, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, castration-resistant prostate carcinoma, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, hiv infection, metastatic differentiated thyroid gland carcinoma, metastatic head and neck carcinoma, metastatic hepatocellular carcinoma, metastatic kaposi sarcoma, metastatic lung non-small cell carcinoma, metastatic lung small cell carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic ovarian carcinoma, metastatic prostate carcinoma, metastatic renal cell carcinoma, metastatic thyroid gland medullary carcinoma, metastatic triple-negative breast carcinoma, metastatic urothelial carcinoma, recurrent differentiated thyroid gland carcinoma, recurrent head and neck carcinoma, recurrent hepatocellular carcinoma, recurrent kaposi sarcoma, recurrent lung non-small cell carcinoma, recurrent lung small cell carcinoma, recurrent malignant solid neoplasm, recurrent melanoma, recurrent ovarian carcinoma, recurrent prostate carcinoma, recurrent renal cell carcinoma, recurrent thyroid gland medullary carcinoma, recurrent triple-negative breast carcinoma, recurrent urothelial carcinoma, refractory differentiated thyroid gland carcinoma, stage iii differentiated thyroid gland carcinoma ajcc v8, stage iii hepatocellular carcinoma ajcc v8, stage iii lung cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iii thyroid gland medullary carcinoma ajcc v8, stage iv differentiated thyroid gland carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iv lung cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv prostate cancer ajcc v8, stage iv renal cell cancer ajcc v8, stage iv thyroid gland medullary carcinoma ajcc v8